Eupraxia Pharmaceuticals Inc.

NASDAQ:EPRX

Biotechnology

Healthcare
$6.21 +1.11%

+$0.07 today

Market cap
$417.57M
Beta
1.48
P/E (TTM)
-8.5
EPS (TTM)
-$0.74
52W Low $4.19High $9.32

Volume 1.21M

Average 0.22M

EPRX Income Tax Expense

Income taxes recognized for the period, including current and deferred tax.

Eupraxia Pharmaceuticals Inc.NASDAQ: EPRX

Income Tax Expense · Q1 FY2026 · quarter ended Mar 2026

Income tax expense grows, but more slowly than its trailing trend

Q1 FY2026 income tax expense of $13.71K rose 390.9% year over year, behind the +7553.1% change in trailing-twelve-month income tax expense. Sequentially, it rose 20.9% from the prior quarter.

Context

  • Income tax expense increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from +390.9% toward the trailing-twelve-month pace of +7553.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$13.71K+20.9% QoQ
Last fiscal yearDec 2025
$26.65K+1379.1% YoY
LTMMar 2026
$30.19K+7553.1% YoY
Income Tax Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+390.9%——
1 year+1379.1%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Tax Expense history

Mixed currencies · from the income statement

Latest · FY2025
26.65K USD
Year-over-year change
+1379.1%

Income Tax Expense vs competitors

How EPRX compares with its peers on the latest reported figures

  • Peers report in different currencies, so income tax expense is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +7553.1% is the highest of 4, against a peer median of -93.0%.
EPRX Competitors
Income Tax Expense for EPRX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MDWDMediWound Ltd.LTM Mar 2026$147K USD+250.0%+29.4%1.0%
EPRXEupraxia Pharmaceuticals Inc.LTM Mar 2026$30.19K USD+7553.1%——
IVAInventiva S.A.FY2025€22K EUR-93.0%—0.5%
SLSSELLAS Life Sciences Group, Inc.LTM Sep 2026$0 USD———
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 2026$0 USD——0.0%
NAUTNautilus Biotechnology, Inc.LTM Mar 2026$0 USD———
TARAProtara Therapeutics, Inc.LTM Mar 2026$0 USD———
NTHINeonc Technologies Holdings, Inc.LTM Mar 2026$0 USD———
AARDAardvark Therapeutics, Inc. Common StockLTM Mar 2026$0 USD———
RNACCartesian Therapeutics, Inc.LTM Mar 2026-$9.19M USD-3303.1%—517.9%
Peer median (excluding EPRX) —-93.0%+29.4%0.8%

Competitors are the stored peer set for EPRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

Mixed currencies
Metric
FY2021
Dec 2021 · CAD
FY2022
Dec 2022 · CAD
FY2023
Dec 2023 · USD
FY2024
Dec 2024 · USD
FY2025
Dec 2025 · USD
Revenue00000
Cost of Revenue112.38K00163.47K331.89K
Gross Profit(112.38K)00(163.47K)(331.89K)
Gross Margin—————
Research & Development7.59M13.63M15.33M16.07M29.51M
Selling, General & Admin6.97M3.99M5.63M10.92M17.1M
Operating Expenses14.65M17.62M20.97M26.99M53.33M
Depreciation & Amortization87.47K147.89K117.1K171.6K331.89K
EBITDA(17.22M)(17.86M)(20.78M)(24.95M)(53.33M)
EBITDA Margin—————
Operating Income(14.65M)(17.62M)(20.97M)(26.99M)(53.66M)
Operating Margin—————
Interest Income51.55K431.8K649.75K1.16M1.41M
Interest Expense1.02M982.86K881.05K603.17K0
Other Income / Expenses(3.68M)(1.37M)(814.93K)1.26M(212.94K)
Income Before Tax(18.33M)(18.99M)(21.78M)(25.73M)(53.87M)
Pre-Tax Margin—————
Income Tax Expense0027.42K1.8K26.65K
Net Income(18.03M)(18.49M)(21.25M)(25.49M)(53.86M)
Net Margin—————
EPS (Basic)(1.63)(0.96)(0.88)(0.76)(1.05)
EPS (Diluted)(1.63)(0.96)(0.88)(0.76)(1.05)
Weighted Avg Shares14.24M19.29M24.15M33.93M39.96M
Weighted Avg Shares (Diluted)14.24M19.29M24.15M33.93M39.96M

Eupraxia Pharmaceuticals Inc.

NASDAQ:EPRX

Intrinsic Alpha fair value

Locked

Current Price

$6.21

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.